Table 3.
Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|
OR (95% CI) | p value | OR (95% CI) | p value | |
Age | 1.003 (0.968–1.038) | 0.878 | – | – |
Sex, male | 2.415 (0.601–9.718) | 0.214 | – | – |
Annual relapse rate | 1.404 (0.893–2.203) | 0.141 | – | – |
Persistently enhancing lesions | 3.654 (1.112–12.001) | 0.033* | 5.473 (1.417–21.115) | 0.014* |
First attack | 0.271 (0.080–0.913) | 0.035* | 0.226 (0.059–0.862) | 0.029* |
AQP4-IgG positive | 0.655 (0.153–2.801) | 0.569 | 0.823 (0.162–4.178) | 0.814 |
Delay from onset to treatment | 0.912 (0.803–1.034) | 0.152 | – | – |
Qalb | 1.015 (0.924–1.116) | 0.751 | 1.073 (0.956–1.203) | 0.225 |
Relapse prevention treatment | 0.787 (0.140–4.419) | 0.786 | – | – |
Qalb = CSF albumin/serum albumin; OR = odds ratio; CI = confidence interval.
*p < 0.05 representing statistical significance.